Modulair (Montelukast)

Montelukast, the active ingredient in Modulair, is a leukotriene receptor antagonist presented as an oral tablet (strength not specified) for oral administration. It helps control asthma, prevents exercise‑induced bronchoconstriction, and relieves symptoms of allergic rhinitis in both adults and children.

GNH USA supplies Modulair as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality standards and regulatory oversight. The company ensures traceability, proper packaging, and compliance with EU marketing authorisation requirements for each batch.

Modulair (montelukast) is a leukotriene receptor antagonist used to treat conditions mediated by cysteinyl leukotrienes. - Asthma: reduces frequency of wheezing episodes and improves lung function. - Exercise‑induced bronchoconstriction: prevents narrowing of the airways during physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itchy eyes.

Adverse reactions may occur with any medication and should be monitored.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Mood changes including depression or suicidal thoughts - Liver enzyme elevations

Before prescribing Modulair, clinicians should consider several safety aspects. - Assess asthma control: ensure patient is on appropriate baseline therapy. - Monitor for neuropsychiatric events: watch for mood changes or suicidal ideation. - Use with caution in hepatic impairment: dose adjustment may be required. - Avoid in patients with known hypersensitivity to montelukast or any tablet excipients. - Review concomitant medications for potential interactions. - Store at room temperature: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines; some interactions require avoidance while others need monitoring.

Major Interactions (Avoid): - Phenobarbital: enzyme induction reduces montelukast exposure. - Rifampin: strong inducer of metabolism, decreasing effectiveness. - Ketoconazole: inhibits metabolism, potentially increasing systemic levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR; monitor coagulation parameters. - Beta‑agonists: may diminish bronchodilator response; assess clinical effect.